Asymmetric Monomer-Dimer Hybrid Proteins for Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chimeric proteins comprising biologically active molecules often face challenges in crossing epithelial barriers and interacting with target molecules due to steric hindrance and self-aggregation, particularly when formulated as homodimers or higher-order multimers, which limits their therapeutic efficacy.
Innovation Solution
Development of monomer-dimer hybrid chimeric proteins, where only one chain comprises a biologically active molecule linked to an immunoglobulin constant region, while the second chain consists of an immunoglobulin constant region without a biologically active molecule, enhancing transport efficiency and reducing steric hindrance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If chimeric proteins are formulated as homodimers or higher-order multimers, then stability and serum half-life are improved, but steric hindrance and self-aggregation increase, limiting therapeutic efficacy
Solution Approach 1:
The patent applies asymmetry by creating monomer-dimer hybrid chimeric proteins where one polypeptide chain contains the biologically active molecule while the other chain serves as a stabilizing partner without the active molecule. This asymmetric structure provides the stability of dimers while reducing steric hindrance compared to symmetric homodimers, as only one chain carries the potentially bulky active molecule.
Solution Approach 2:
The invention segments the dimer structure by having one chain modified with the biologically active molecule and the other chain unmodified. This segmentation allows the stabilizing Fc portion to be provided by both chains while the therapeutic function is concentrated in one chain, reducing intermolecular interference.
2Stability of the object's composition
If chimeric proteins are formulated as homodimers or higher-order multimers, then stability and serum half-life are improved, but accessibility to target cells is reduced due to self-aggregation
Solution Approach 1:
The asymmetric monomer-dimer hybrid structure ensures that only one of the two chains contains the biologically active molecule, reducing self-aggregation compared to homodimers where both chains carry active molecules that may interfere with each other's target binding.
Solution Approach 2:
The invention applies local quality by concentrating the biologically active molecule in one specific chain while the other chain provides stabilizing properties. This localized distribution improves target cell accessibility at the active site while maintaining overall protein stability through the partner chain.
3Stability of the object's composition
If chimeric proteins are formulated as homodimers, then biological stability is enhanced, but dosing frequency must be reduced due to lower bioavailability
Solution Approach 1:
The monomer-dimer hybrid asymmetric structure improves bioavailability compared to homodimers by reducing steric hindrance and self-aggregation, allowing better absorption and distribution while maintaining the stability benefits of dimeric structure through the unmodified partner chain.
Data Source
AI summary
The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.